Sign in

SCMP on NASDAQ

Sucampo Pharmaceuticals

Defunct pharmaceutical company

Sucampo Pharmaceuticals, Inc. was a pharmaceutical company headquartered in Rockville, Maryland that focused on gastroenterology, ophthalmology, and oncology-related disorders. In 2018, the company was acquired by Mallinckrodt. Sucampo had two marketed products, Amitiza, which treats constipation issues and Rescula, which helps treat ocular hypertension and open-angle glaucoma.3 It was founded by Sachiko Kunō.1 Its shares trade on NASDAQ under the symbol SCMP.1 Wikipedia text CC BY-SA 4.0

Price unavailable

Last updated Oct 21, 2026.

Overview

1996Founded1

Compare with another stock.

  • TickerSCMP on NASDAQ1
  • Industrypharmaceutical industry1
  • HeadquartersRockville1
  • Websitewww.sucampo.com
  • Legal formDelaware corporation1
  • Business address805 King Farm Boulevard, Suite 550, Rockville, Md 208505
  • Filer categoryAccelerated filer5
  • LEI549300YPLK5FSJFMAH244
  • StatusActive4
  • LEI statusLapsed (not renewed)4
  • Registered addressC/O Corporation Service Company, 19808 Wilmington, United States4
  • Registered withDivision of Corporations, Department of State, 46305064

See how the biggest companies compare on our leaderboards

Sucampo Pharmaceuticals, Inc. was a pharmaceutical company headquartered in Rockville, Maryland that focused on gastroenterology, ophthalmology, and oncology-related disorders. In 2018, the company was acquired by Mallinckrodt.3

Corporate structure

Sucampo Pharmaceuticals sits at the top of its group. 3 entities, 2 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

  • Sucampo Pharmaceuticals Rockville, Maryland, United States
    • Sucampo (Switzerland) Subsidiary · Zug, Switzerland
    • SUCAMPO PHARMA, LLC Subsidiary · Hazelwood, Missouri, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries, stakes and holdings from Wikidata (CC0). Each entity in the chart links to its source.

What it owns

What Sucampo Pharmaceuticals reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$9.9M7 Dec 31, 2016$10.0M7 Dec 31, 2015−0.3%
Accumulated depreciation$3.7M7 Dec 31, 2016$3.6M7 Dec 31, 2015+4.1%
Property and equipment, net$6.2M7 Dec 31, 2016$6.4M7 Dec 31, 2015−2.8%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$198.3M7 Dec 31, 2016$108.3M7 Dec 31, 2015+83.1%
Long-term investments$5.5M7 Dec 31, 2016$13.5M8 Dec 31, 2014−59.4%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$73.0M7 Dec 31, 2016$60.9M7 Dec 31, 2015+19.8%
Indefinite-lived intangibles (excluding goodwill)$6.2M7 Dec 31, 2015
Accumulated amortization$34.1M7 Dec 31, 2016$8.5M7 Dec 31, 2015+303.4%
Finite-lived intangibles, net$128.1M7 Dec 31, 2016$130.3M7 Dec 31, 2015−1.7%

Inventory

ItemLatestA year beforeChange
Inventory, total$23.5M7 Dec 31, 2016$33.1M7 Dec 31, 2015−29.1%
Raw materials$1.4M7 Dec 31, 2016$5.6M7 Dec 31, 2015−74.5%
Work in process$18.0M7 Dec 31, 2016$26.9M7 Dec 31, 2015−33.0%
Finished goods$4.0M7 Dec 31, 2016$641.0K7 Dec 31, 2015+525.4%

The story

Founded by Sachiko Kunō in 1996.1

The company was founded by Ryuji Ueno and Sachiko Kuno in 1996.

In January 2006, the company received approval from the Food and Drug Administration for Amitiza.

In 2010, the company entered into arbitration with its partner, Takeda Pharmaceutical Company, claiming that sales of Amitiza floundered because of a half-hearted marketing effort by Takeda. Sucampo lost the arbitration.

In late 2015, the company moved its headquarters from Bethesda, Maryland to Rockville, Maryland.

In January 2016, the company acquired an option for an exclusive license to a drug to treat familial adenomatous polyposis.

In April 2017, the company acquired Vtesse.

In February 2018, the company was acquired by Mallinckrodt. At that time, the founders owned a combined 30% of the company.

From Wikipedia’s article on Sucampo Pharmaceuticals, shared under CC BY-SA 4.0.6

Leadership

Who has led Sucampo Pharmaceuticals, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Ryuji Ueno2007–2014
  2. Peter Greenleaf2014–2018

President

  1. Stanley G. Miele2010–2015

Chief financial officer

  1. Ronald W. Kaiser2007
  2. Cary J. Claiborne2011–2014
  3. Andrew P. Smith2015–2017
  4. Peter P. Pfreundschuh2017–2018
200020052010201520202025
Board members and other officers (37)

Products and brands

  • lubiprostone

Listed on Wikidata.1

Subsidiaries and ownership

Subsidiaries

From Wikidata.1

Timeline

  1. Feb 12, 2018Dissolved Dissolved1
  2. Mar 5, 2014New chief executive Peter Greenleaf becomes CEO9
  3. Aug 2, 2007New chief executive Ryuji Ueno becomes CEO10
  4. 1996Founded Founded1

SEC filer profile

How Sucampo Pharmaceuticals is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARSucampo Pharmaceuticals, Inc.2
  • CIK0001365216
  • Employer ID (EIN)13-39292372
  • Filer statusAccelerated filer2
  • Fiscal year endsDecember 312
  • Industry code (SIC)2834 Pharmaceutical Preparations2
  • Business address805 King Farm Boulevard, Suite 550, Rockville, MD 208502
  • Phone30196134002
  • Shares outstanding46,636,924 as of Oct 26, 201751
  • Public float$238.3M as of Jun 30, 20167
  • On EDGAR sinceJun 19, 20062
  • Filings862 in all: 4 (345), 8-K (212), 3 (47), SC 13G/A (35), 10-Q (32), 5 (16), CORRESP (16), SC 13G (16)2
    All 41 form types

    UPLOAD (15), 8-K/A (11), CT ORDER (11), 10-K (10), DEF 14A (10), SC 13D/A (10), EFFECT (9), S-1/A (9), SC TO-T/A (8), SC 14D9/A (7), SC 13D (5), POS AM (4), S-3 (4), 10-K/A (3), 4/A (3), S-8 POS (3), 424B3 (2), FWP (2), S-8 (2), SC 14D9 (2), 15-12B (1), 25-NSE (1), 3/A (1), 424B4 (1), 8-A12B (1), 8-A12B/A (1), CERTNAS (1), DEFA14A (1), S-1 (1), S-3/A (1), SC TO-C (1), SC TO-T (1), SC14D9C (1)

  • Latest filingsAnnual report (10-K) Mar 8, 2017
    Quarterly report (10-Q) Nov 1, 2017
    Proxy statement (DEF 14A) Apr 21, 2017
    Latest 8-K (8-K) Feb 13, 2018

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51